157 related articles for article (PubMed ID: 35456397)
61. Incidental Splenic Marginal Zone Lymphoma With Extreme Macrocytosis After Hydroxyurea Use: A Case Report.
Sultan K; Kal S; Wasson A; Farmand F
Cureus; 2023 Jan; 15(1):e33462. PubMed ID: 36751210
[TBL] [Abstract][Full Text] [Related]
62. Case report: Salivary duct carcinoma in a patient with a germline
Desai N; Racila E; Fujioka N; Gupta A; Antonarakis ES
Front Oncol; 2024; 14():1372382. PubMed ID: 38651154
[TBL] [Abstract][Full Text] [Related]
63. Splenic marginal zone lymphoma: a case report and literature review.
Zhang S; Xuan Z; Zhang L; Lu J; Song P; Zheng S
World J Surg Oncol; 2020 Oct; 18(1):259. PubMed ID: 33004051
[TBL] [Abstract][Full Text] [Related]
64. Protection of telomeres 1 protein levels are associated with telomere length in gastric cancer.
Fujii K; Sasahira T; Moriwaka Y; Oue N; Yasui W; Kuniyasu H
Int J Mol Med; 2008 May; 21(5):599-604. PubMed ID: 18425352
[TBL] [Abstract][Full Text] [Related]
65. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.
Calvete O; Martinez P; Garcia-Pavia P; Benitez-Buelga C; Paumard-Hernández B; Fernandez V; Dominguez F; Salas C; Romero-Laorden N; Garcia-Donas J; Carrillo J; Perona R; Triviño JC; Andrés R; Cano JM; Rivera B; Alonso-Pulpon L; Setien F; Esteller M; Rodriguez-Perales S; Bougeard G; Frebourg T; Urioste M; Blasco MA; Benítez J
Nat Commun; 2015 Sep; 6():8383. PubMed ID: 26403419
[TBL] [Abstract][Full Text] [Related]
66. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.
Cabrero M; Yu Y; Verma A; Yang H; Colla S; Jia Y; Zheng H; Bohannan Z; Ganan-Gomez I; Futreal A; Takahashi K; Chin L; Kantarjian H; Pellagatti A; Bowman T; Boultwood J; Garcia-Manero G; Wei Y
Br J Haematol; 2016 Apr; 173(1):161-5. PubMed ID: 26105212
[No Abstract] [Full Text] [Related]
67. Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene.
Mateo MS; Mollejo M; Villuendas R; Algara P; Sanchez-Beato M; Martínez P; Piris MA
Leukemia; 2001 Apr; 15(4):628-34. PubMed ID: 11368366
[TBL] [Abstract][Full Text] [Related]
68. CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.
Schmieg JJ; Muir JM; Aguilera NS; Auerbach A
Curr Oncol; 2021 Dec; 28(6):5124-5147. PubMed ID: 34940069
[TBL] [Abstract][Full Text] [Related]
69. G-quadruplex-mediated regulation of telomere binding protein POT1 gene expression.
He Q; Zeng P; Tan JH; Ou TM; Gu LQ; Huang ZS; Li D
Biochim Biophys Acta; 2014 Jul; 1840(7):2222-33. PubMed ID: 24631651
[TBL] [Abstract][Full Text] [Related]
70. Splenic marginal zone lymphoma.
Piris MA; Onaindía A; Mollejo M
Best Pract Res Clin Haematol; 2017; 30(1-2):56-64. PubMed ID: 28288718
[TBL] [Abstract][Full Text] [Related]
71. Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
Defrancesco I; Zibellini S; Boveri E; Frigeni M; Ferretti VV; Rizzo E; Bonometti A; Capuano F; Candido C; Rattotti S; Tenore A; Picone C; Flospergher E; Zerbi C; Bergamini F; Fabbri N; Cristinelli C; Varettoni M; Paulli M; Arcaini L
Hematol Oncol; 2020 Dec; 38(5):689-697. PubMed ID: 32738175
[TBL] [Abstract][Full Text] [Related]
72. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Herling CD; Klaumünzer M; Rocha CK; Altmüller J; Thiele H; Bahlo J; Kluth S; Crispatzu G; Herling M; Schiller J; Engelke A; Tausch E; Döhner H; Fischer K; Goede V; Nürnberg P; Reinhardt HC; Stilgenbauer S; Hallek M; Kreuzer KA
Blood; 2016 Jul; 128(3):395-404. PubMed ID: 27226433
[TBL] [Abstract][Full Text] [Related]
73. A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma.
Yilmaz E; Chhina A; Nava VE; Aggarwal A
Curr Oncol; 2021 Dec; 28(6):5148-5154. PubMed ID: 34940070
[TBL] [Abstract][Full Text] [Related]
74. RPA and POT1: friends or foes at telomeres?
Flynn RL; Chang S; Zou L
Cell Cycle; 2012 Feb; 11(4):652-7. PubMed ID: 22373525
[TBL] [Abstract][Full Text] [Related]
75. [Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow].
Sun Q; Zhang PH; Liu EB; Liu W; Li ZQ; Yang QY; Fang LH; Sun FJ; Chen HS; Qiu LG
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):234-8. PubMed ID: 23928529
[TBL] [Abstract][Full Text] [Related]
76. Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32.
Boonstra R; Bosga-Bouwer A; van Imhoff GW; Krause V; Palmer M; Coupland RW; Dabbagh L; van den Berg E; van den Berg A; Poppema S
Mod Pathol; 2003 Dec; 16(12):1210-7. PubMed ID: 14681321
[TBL] [Abstract][Full Text] [Related]
77. Mutations in POT1 predispose to familial cutaneous malignant melanoma.
Trigueros-Motos L
Clin Genet; 2014 Sep; 86(3):217-8. PubMed ID: 24784786
[No Abstract] [Full Text] [Related]
78. Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.
Butler KS; Hines WC; Heaphy CM; Griffith JK
Cancer Med; 2012 Oct; 1(2):165-75. PubMed ID: 23342266
[TBL] [Abstract][Full Text] [Related]
79. [Pathologic characteristics of bone marrow for
CD5 positive small B cell lymphoma].
Peng S; Zhu F; You S; Gong M; Wen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Apr; 41(4):374-9. PubMed ID: 27241147
[TBL] [Abstract][Full Text] [Related]
80. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
Mirabello L; Zhu B; Koster R; Karlins E; Dean M; Yeager M; Gianferante M; Spector LG; Morton LM; Karyadi D; Robison LL; Armstrong GT; Bhatia S; Song L; Pankratz N; Pinheiro M; Gastier-Foster JM; Gorlick R; de Toledo SRC; Petrilli AS; Patino-Garcia A; Lecanda F; Gutierrez-Jimeno M; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Kurucu N; Ilhan IE; Ballinger ML; Thomas DM; Barkauskas DA; Mejia-Baltodano G; Valverde P; Hicks BD; Zhu B; Wang M; Hutchinson AA; Tucker M; Sampson J; Landi MT; Freedman ND; Gapstur S; Carter B; Hoover RN; Chanock SJ; Savage SA
JAMA Oncol; 2020 May; 6(5):724-734. PubMed ID: 32191290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
